[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"late-effect-of-radiation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:late-effect-of-radiation":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100520029","phase-2-lithium-treatment-to-prevent-cognitive-impairment-after-brain-radiotherapy-100520029",false,"NCT06051240","Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy","LiBRA","Inclusion Criteria:\n\n* Age \\>5 years.\n* Age \\\u003C18 years at time of radiotherapy.\n* Has received cranial\u002Fcraniospinal radiation treatment of brain tumor within the last 7 years.\n* Adequate contraceptive method to prevent pregnancy\\* during the entire lithium treatment period and six months thereafter.\n* Negative pregnancy test\\* at screening, at start of study treatment, and monthly thereafter.\n* Written informed consent from patient and\u002For caregiver.\n\nExclusion Criteria:\n\n* Allergy\u002Fhypersensitivity to lithium or any of the excipients\n* Renal failure (Cystatin C derived Glomerular Filtration Rate \\\u003C 60).\n* Cardiac failure or heart disease, including Brugada syndrome (or family history thereof).\n* Uncontrolled hypothyroidism.\n* Pregnancy or breast feeding.\n* Severe fluid or electrolyte imbalance.\n* Karnofsky-Lansky score \\\u003C 60.\n* Other condition deemed incompatible with inclusion in this study (estimated 2 year survival prognosis less than 25 %, expected poor protocol compliance, inability to swallow tablets, language difficulties).\n* Inclusion in other study protocol precluding inclusion in this study.","ALL","5 Years",{"count":19,"type":20},84,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol\u002Fl) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors.\n\nPrimary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.",[26,27,28,29,30,31,32],"Cognitive Impairment","Cognitive Decline","Radiotherapy Side Effect","Radiotherapy; Complications","Brain Tumor","Memory Impairment","Late Effect of Radiation",[34,35,36,37,38,39,40,41,42,43],"lithium","neuroprotection","neuroprotective","regenerative","prevention","radiation","pediatric brain tumor","brain tumor","cognition","cognitive","RECRUITING","2024-04-11",{"date":47,"type":48},"2024-04-12","ACTUAL",{"date":50,"type":48},"2024-02-16",{"date":52,"type":20},"2033-08-31",{"name":54,"class":55},"Region Stockholm","OTHER_GOV",2]